LY2584702 Tosylate (also known as LYS6K2), the tosylate salt of LY2584702, is a selective, orally bioavailable, and ATP-competitive p70S6K (ribosomal p70 S6 kinase) inhibitor with potential antitumor activity.

LY2584702 is a novel, selective, orally bioavailable, and ATP-competitive inhibitor of p70S6K (ribosomal p70 S6 kinase) with potential antitumor activity.

PF-4708671 is a novel, potent, highly specific and cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform)/RSK1 with potential antitumor activity.

LJI308 is a novel, potent, and pan-RSK (p90 ribosomal S6 kinase) inhibitor with potential antitumor activity.

H 89 2HCl, the dihydrochloride salt of H 89 (H-89), is a novel, potent and cAMP-dependent inhibitor of PKA (protein kinase A) with the potential to attenuates prominent behavioral signs of morphine withdrawal in morphine-dependent mice.

BI-D1870 is a specific, cell permeable and ATP-competitive inhibitor of RSK1/2/3/4 (p90 ribosomal S6 kinase) with the potential to treat autoimmune encephalomyelitis (EAE).